Skip to main content
Clinical Trials/ChiCTR-OCH-12002611
ChiCTR-OCH-12002611CompletedPhase 4

基因多态对血管紧张素转化酶抑制剂治疗中国高血压病人疗效的影响

自筹1 site in 1 country1,000 target enrollmentStarted: June 6, 2007Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
1,000
Locations
1
Primary Endpoint
高血压相关基因

Study Overview

Brief Summary

阐明基因多态性与高血压及其药物疗效与不良反应之间关系的研究

Study Design

Study Type
观察性研究
Primary Purpose
队列研究

Eligibility Criteria

Ages
18 to 90 (—)
Sex
All

Inclusion Criteria

  • 明确诊断为原发性高血压的患者,在未服药的情况下,坐位收缩压≥140 mmHg 且 <180 mmHg 和(或)坐位舒张压≥90mmHg 且<110 mmHg。

Exclusion Criteria

  • 排除继发性高血压、孕妇或哺乳期妇女等患者

Arms & Interventions

正常对照组

高血压组

高血压药物

Outcomes

Primary Outcomes

高血压相关基因

血压值

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
自筹

Study Sites (1)

Loading locations...

Similar Trials